Background: To compare the RVO incidence for OAG patients with that for the general population in order to determine the association between RVO and OAG.
INTRODUCTION
Retinal vein occlusion (RVO) is a common sightthreatening retinal vascular disorder. [1] [2] [3] [4] The retinal artery compresses the inferior retinal vein, the resultant hemodynamic changes leading to the formation of thrombi. [4] [5] [6] [7] Glaucoma, the signatures of which are loss of retinal ganglion cells and visual-field defect, is the most common cause of irreversible blindness worldwide. 8 The correlation between RVO and open-angle glaucoma (OAG) has been reported in many previous studies. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Indeed, RVO and glaucoma share common associated vascular disorders such as systemic hypertension, [22] [23] [24] [25] diabetes mellitus 24, 26 and insulin-resistance. 27 Based on these and other indications, the hypothesis of a common vascular pathogenesis has gained a great deal of support. [23] [24] [25] On the other hand, a recent hospital-based study reported that two diseases are less likely to have a common vascular pathogenesis in consideration of the prevalence of glaucoma in RVO patients. 20 If RVO and OAG do, in fact, share a common vascular pathogenesis, RVO incidence in OAG patients might be higher than that in the general population. To compare the incidence of RVO in OAG patients and the general population, significantly large population-based studies are necessary.
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METHODS
We analysed the Korean Health Insurance Review and Assessment (HIRA) data for 2011 through 2015.
The Korean National Health Insurance (NHI) scheme, a compulsory form of social insurance, covers approximately 97% of the Korean population. In general, patients insured by NHI pay approximately 30% of their total medical expenses, all health-care providers are required to submit claims for the remaining 70%. The claims consist of demographic information, diagnoses, procedures, prescription records, demographic information and direct medical costs. All submitted health claims are reviewed by HIRA, referencing the Korean Classification of Disease (sixth edition), a modified version of the International Classification of Diseases (tenth edition). Those among the Korean population who are not insured by NHI are covered by the Medical Assistance Program or the Medical Care for Patriots and Veterans Affair scheme. The claims submitted under these two schemes also are reviewed by HIRA. The HIRA database thus covers the entire Korean population and their medical claims. Access to the HIRA database is restricted, being permitted only after approval by HIRA Deliberative Committee for studies that are conducted for the common good. For the purposes of the present study, we were provided access to the data representing the years 2011 through 2015. The study was approved by the Seoul National University Hospital Institutional Review Board and was conducted in accordance with the tenets of the Declaration of Helsinki.
In this study, we determined and compared the RVO incidence rates for OAG patients and the general population in order to isolate evidence for any association between RVO and OAG. First, the person-time incidence rates of clinically diagnosed RVO in the general Korean population during the 4-year study period (2012) (2013) (2014) (2015) were calculated and classified according to age and gender. The population at risk was defined as the entire Korean population, as enumerated in the Population and Housing Census (PHC) of 2015 available from the Korean Statistical Information Service (http://kosis.kr). We identified the RVO patients registered during the study period by RVO code (H.348), excluding cases that had a RVO code in 2011 in order to remove any potential pre-existing cases of RVO. The index date was defined as the date of the earliest RVO-coded claim in that period (2012) (2013) (2014) (2015) . This date was considered to be the incident time, and the patient was considered to be an incident case in that year. The person-time incidence rates of RVO in general Korean population were calculated as the numbers of people in whom RVO developed in each year from 2012 through 2015 divided by the total number of the general Korean population. Finally, the frequency and estimated incidence rates were classified according to age and gender.
Second, the person-time incidence rates of clinically diagnosed RVO in OAG patients during the 4-year study period (2012-2015) were calculated and classified according to age and gender. We identified OAG patients registered in 2011 by the OAG code (H.401) and excluded those that had an RVO code (H.348) during the same year (2011) in order to remove any potential pre-existing cases of RVO. The remaining cases were considered OAG patients without previous RVO. For each of these cases, we identified the first RVO code registered within the 2012-2015 study period. The index date was defined as the date of the earliest RVO-coded claim within the period. This was considered to be the incident time, and the patient was considered to be an incident case in that year. The person-time incidence rates of RVO in OAG patients were calculated as the numbers of people in whom RVO developed in each year from 2012 through 2015 divided by the total number of OAG patients without previous RVO in 2011. Finally, the frequency and estimated incidence rates were classified according to age and gender.
Third, the RVO incidence rate for OAG patients was compared to that for the general Korean population. The general population was set as the reference group, and the expected RVO incidences for each of the OAG age and gender groups were estimated by multiplying the age-and gender-specific incidence rates of the general Korean population by the numbers of persons in each of those groups. The expected RVO incidence rate for the OAG patients, as age-and gender-adjusted, was calculated by dividing the total number of expected incidences by the total number of OAG patients. The standardized incidence ratio (SIR) was calculated as the observed-to-expected RVO incidence ratio among the OAG patients.
The 95% confidence interval (CI) of the incidence rate was estimated based on the Poisson distribution. SAS software version 9.3 (SAS Inc., Cary, NC, USA) was used for all of the analyses. P values less than 0.05 were considered statistically significant.
RESULTS
According to the 2015 PHC, the Korean population was 49 705 663. The numbers of Korean men and women were 24 819 839 (49.9%) and 24 885 824 (50.1%), respectively ( Table 1) .
In total, 147 452 clinically diagnosed RVO cases were identified in the general Korean population during the 4-year study period (2012) (2013) (2014) (2015) We identified 279 079 OAG patients registered in 2011. Among them, 6936 (2.49%) had a RVO code for the same year. Consequently, the other 272 143 OAG patients were defined as the population at risk for the determination of RVO incidence in cases of OAG. The numbers of male and female OAG patients were 132 198 (48.6%) and 139 945 (51.4%), respectively ( Table 2) .
In total, 5758 clinically diagnosed RVO cases were identified among the OAG patients during the 4-year study period (2012) (2013) (2014) (2015) . The number of RVO cases in men and women were 2751 (47.8%) and 3007 (52.2%), respectively. The number of RVO cases in 2012, 2013, 2014 and 2015 were 1638 (28.4%), 1640 (28.5%), 1294 (22.5%) and 1186 (20.6%), respectively. The 4-year RVO incidence rate for the OAG patients was 528.95 per 100 000 person-years (95% CI, 515.46-542.79). The RVO incidence rates for men and women were 520.24 (95% CI, 501.16-540.05) and 537.18 (95% CI, 518.31-556.72), respectively ( Table 2) .
With the general Korean population set as the reference group, the expected incidences of RVO for all of the OAG patients were 1760.66 during the 4-year study period (2012-2015). On the other hand, the number of observed RVO incidences, 5758, was significantly higher. The SIR was 3.27 (95% CI, 3.19-3.35), indicating that the RVO incidence was 227% higher for OAG patients than for the general population, which was statistically significant. The SIRs for men and women were 3.77 (95% CI, 3.63-3.91) and 2.91 (95% CI, 2.81-3.02), respectively (Table 3) (Fig. 1) .
DISCUSSION
In the present study, we determined the RVO incidence rates for OAG patients and the general population, respectively, and then compared them by SIR and age-and gender adjustment.
Park et al., 29 using the 2007-2011 HIRA data, reported, for the general Korean population, an incidence rate of clinically diagnosed RVO of 48.61 per 100 000 person-years (95% CI, 41.99-42.81). In the present study, the RVO incidence rate for the 2012-2015 period was higher: 74.16 per 100 000 person-years (95% CI, 73.79-74.54). This discrepancy might reflect differences in the study population ages. The mean age of the Korean population in the 2015 PHC is higher than that in the 2010 PHC (40.4 vs. 38.1). Also, the percentage of the 70-74 age group, which showed the highest RVO incidence rate in both studies, increased from 3.26% to 3.54% between the two censuses. Other factors, such as increased health screening including fundus examinations, might also have had effects, and so further research is needed.
Based on a previous Korean population-based study, Kim et al. 30 reported for the 40 years and older demographic, an OAG prevalence of 4.7% and a disease awareness of 8.0%. Among them, 79.4% had been receiving glaucoma treatment, or about 0.30% of the Korean population of that age. In the present study, the number of OAG patients registered in 2011 was 279 079. Considering that most glaucoma patients have a regular check-up at least once a year, we supposed that that was also the total number of OAG patients receiving glaucoma treatment in Korea. Among them, the number of OAG patients 40 years and older was 247 045, or 0.96% of the Korean population of the same age.
Many studies have reported the association between RVO and glaucoma, particularly OAG. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Among these studies, some have compared RVO incidence rates between glaucoma patients and the general population.
12,21 Hirota et al. 12 determined that the RVO incidence among a total of 433 glaucoma patients was 18 (4.2%), whereas the incidence for a general outpatient clinic was only 0.59%. Another population-based study reported the RVO incidence rate over a 4-year period for those aged 40 years and older: in fact, the rate for glaucoma patients was much higher than for the remainder of The Korean OAG population was identified as OAG patients registered in 2011 according to the OAG code (H.401), and the cases that had an RVO code (H.348) during the same year (2011) were excluded. ‡ The incidence rate unit is 100 000 person-years. §
The 95% confidence interval (CI) was calculated based on the Poisson distribution. The Korean OAG population was identified as OAG patients registered in 2011 according to the OAG code (H.401), and the cases that had an RVO code (H.348) during the same year (2011) were excluded. ‡ The incidence rate unit is 100 000 person-years. §
The standardized incidence ratio (SIR) was derived as the observed-to-expected RVO incidence ratio in the Korean OAG population.
the population (17.3 and 1.85 per 1000, respectively). 21 In the current study, we determined the RVO person-time incidence rate for OAG patients and compared it with that for the general population. We found that, after age-and gender adjustment, the rate for OAG patients was 3.27 times higher than that for the general population. This suggests that OAG is closely associated with RVO development.
Many previous studies on the relationship between RVO and OAG have been reported. Especially in normal-tension glaucoma (NTG), the vascular factor is thought to have, as it does in RVO, an important pathogenetic role. High NTG prevalences have been reported in East Asian nations, including Korea, relative to those in Western countries. In the report on a Korean population-based glaucoma prevalence survey known as the Namil study, 77% of the patients with OAG had an IOP ≤ 21 mmHg. 28 Another Korean population-based study estimated an OAG prevalence of 4.7% among those aged 40 years and older, and of 4.5% among those with an IOP ≤ 21 mmHg. 30 Certainly, the high NTG prevalence in Korean OAG populations can help to clarify the associations between RVO and OAG found in the present study.
This study has several limitations. First, we might have underestimated the RVO incidence rate in the general Korean population, as asymptomatic RVO patients who do not access RVO-related healthcare could not be identified as RVO cases. Second, the observed RVO incidence rate might have been high, as OAG patients who do go to hospitals for regular glaucoma check-ups have a higher chance of having asymptomatic RVO detected than do those who do not. However, there are also factors that could have lowered the observed RVO incidence rate for OAG patients. For example, we could not detect RVO cases among OAG patients for whom the RVO code had not been added to the OAG code despite an observation of RVO during follow-up. The third limitation of this study is the possibility of inaccurate diagnostic coding in claim data; and in fact, we were unable to review the medical records or validate the RVO and OAG diagnoses. Fourth, cases of already-diagnosed RVO could have been included in our recorded incidences. It is not certain whether the 1-year code-free period is in fact sufficient, though we suppose that it is: the RVO incidences in 2012, 2013, 2014 and 2015 had code-free periods of 1, 2, 3 and 4 years, respectively, and they did not differ significantly.
In the present study, using HIRA data, we were able to determine that the RVO incidence rate for OAG patients was significantly higher than that for the general population. Our results suggest that OAG is closely associated with RVO development and that the two diseases might share not only risk factors but also a pathogenesis. Further investigations are needed to validate this hypothesis and to explore alternative potential explanations for our observations. 
